HC Wainwright Predicts Insmed’s Q1 Earnings (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Insmed in a research report issued to clients and investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will post earnings per share of ($1.47) for the quarter. HC Wainwright has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

Other equities analysts also recently issued research reports about the company. Guggenheim reiterated a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday. Royal Bank of Canada began coverage on Insmed in a research report on Tuesday. They set an “outperform” rating and a $100.00 price objective on the stock. Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $91.60.

Insmed Stock Performance

Shares of Insmed stock opened at $77.50 on Monday. Insmed has a one year low of $21.92 and a one year high of $84.91. The company has a market cap of $13.86 billion, a price-to-earnings ratio of -13.86 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business’s 50 day moving average price is $74.43 and its 200 day moving average price is $73.67.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Darwin Global Management Ltd. grew its stake in Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after purchasing an additional 123,429 shares in the last quarter. Capital International Investors grew its stake in Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after purchasing an additional 273,759 shares in the last quarter.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $7,573,950.36. The trade was a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,207 shares of company stock valued at $41,400,465. 4.60% of the stock is currently owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.